Approved indications
Rasagiline is FDA-approved for the treatment of the signs and symptoms of idiopathic Parkinson’s disease in adults, both as initial monotherapy and as an add-on to levodopa or other Parkinson’s medicines.

Off-label uses
Off-label, it has been studied for early or mild parkinsonian conditions and for possible neuroprotective effects, but these uses remain investigational and evidence is not strong enough for routine prescribing specifically for disease modification or non-Parkinson movement disorders.

Efficacy expectations
Many patients notice some improvement in motor symptoms (such as less “off” time, better movement, or less stiffness) within several weeks; benefits may continue to build over 1–2 months of stable dosing. As monotherapy in early Parkinson’s disease, rasagiline typically provides modest symptom relief compared with levodopa but can delay the need for higher-dose levodopa. As an add-on to levodopa, it can reduce daily “off” time by roughly 1 hour or more in many patients, though individual response varies. Compared with other MAO-B inhibitors, its effectiveness is broadly similar; drug choice often depends on side-effect profile, dosing convenience, comorbidities, and cost.

Typical dosing and how to take
For adults with Parkinson’s disease, the usual starting dose is 0.5 mg by mouth once daily; it may be increased to 1 mg once daily depending on response and tolerability, whether used alone or with levodopa. Tablets can be taken with or without food at about the same time each day and should be swallowed whole with water.

Special dosing instructions
In moderate liver impairment, a lower dose or avoidance may be recommended, and rasagiline is generally not used in severe liver impairment. Clinicians may adjust levodopa or other Parkinson medicines when rasagiline is added to reduce dyskinesias or other dopaminergic side effects. Do not exceed 1 mg per day, as higher doses reduce selectivity for MAO-B and increase interaction and side-effect risks.

Missed dose guidance
If a dose is missed, it should be taken as soon as remembered on the same day, unless it is almost time for the next dose; in that case, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one.

Overdose
In case of overdose or if too many tablets are taken, seek emergency medical care or contact a poison control center immediately, as overdose can cause very high blood pressure, severe headache, agitation, or other serious symptoms that require monitoring and supportive treatment.

Common side effects
Common side effects include headache, joint or muscle pain, indigestion or nausea, dry mouth, dizziness or lightheadedness (especially when standing), and flu-like symptoms or fatigue. In people taking levodopa, dyskinesias (involuntary movements) may worsen as rasagiline boosts dopamine effect. These effects are usually mild to moderate and may appear within days to weeks of starting or adjusting the dose.

Serious or rare adverse effects
Seek urgent medical attention for signs of severe allergic reaction (rash, itching/swelling of face or throat, severe dizziness, trouble breathing), chest pain, sudden severe headache, vision or speech changes, confusion, hallucinations, severe uncontrolled movements, or very high blood pressure (severe headache, vision changes, chest pain). Although designed as a selective MAO-B inhibitor at usual doses, combining rasagiline with certain antidepressants, opioids, or other serotonergic drugs can in rare cases trigger serotonin syndrome (agitation, fever, sweating, fast heartbeat, stiff muscles, confusion).

Warnings and precautions
Use with caution in people with a history of low blood pressure when standing, psychosis, or severe psychiatric illness, as it may worsen hallucinations or blood-pressure swings. Dose adjustment or extra monitoring may be needed in moderate liver impairment; it is generally avoided in severe liver disease. Safety in pregnancy and breastfeeding is not well established, so clinicians weigh potential benefits and risks before use. It is not typically used in children, as Parkinson’s disease is rare in this group and rasagiline has not been adequately studied in pediatrics.

Comparative safety
Compared with many dopaminergic drugs, rasagiline has a relatively favorable side-effect profile at recommended doses, with less risk of impulse-control disorders than dopamine agonists and without the motor fluctuations associated with high-dose levodopa alone, though it can amplify levodopa-related dyskinesias. Like other MAO-B inhibitors, it requires attention to drug interactions and blood-pressure effects.

Side-effect reporting and safety updates
Patients and caregivers can report suspected side effects to the FDA’s MedWatch program or to their prescribing clinician and pharmacist, who can also provide up-to-date safety information and monitor for new safety communications.

Drug and supplement interactions
Rasagiline must not be used with other MAO inhibitors or within the recommended washout period of such drugs. It can interact with many antidepressants (SSRIs, SNRIs, tricyclics, MAOIs), certain opioids (such as meperidine, tramadol, methadone), dextromethorphan, and some stimulants, increasing the risk of serotonin syndrome or hypertensive reactions. Strong CYP1A2 inhibitors (such as ciprofloxacin) can raise rasagiline levels, so dose adjustment or avoidance may be needed. Some herbal supplements and OTC products with serotonergic or stimulant properties (such as St. John’s wort) may also interact and should be discussed with a clinician.

Food, alcohol, and procedure interactions
At recommended doses, rasagiline is largely MAO-B–selective, so strict low-tyramine dietary restrictions are generally not required; however, very large amounts of high-tyramine foods (aged cheeses, cured meats, some fermented products) may still pose a small risk of blood-pressure spikes and should be eaten in moderation. Alcohol can worsen dizziness and drowsiness, so intake should be limited and individualized. Before surgery or procedures requiring anesthesia, patients should inform their surgical and anesthesia teams, as certain anesthetic agents and sympathomimetic drugs may require dose adjustments or caution.

Precautions and conditions making use unsafe
Rasagiline is used cautiously or avoided in patients with severe liver impairment, uncontrolled high blood pressure, active psychosis, or a history of certain serious reactions to MAO inhibitors. Clinicians review all current medicines to avoid prohibited combinations that can cause serotonin syndrome or hypertensive crisis.

Monitoring needs
Routine blood tests are not usually required solely for rasagiline, but clinicians often monitor blood pressure (sitting and standing), mental status, and motor symptoms. In patients with liver disease or on interacting drugs, liver function or drug levels may be checked as clinically indicated.

Q: How long does it take for rasagiline to start working?
A: Some people notice improvement in stiffness, slowness, or “off” time within a few weeks, but full benefit may take 1–2 months of regular daily use.

Q: Do I need to follow a special diet while taking rasagiline?
A: At standard doses, strict tyramine-restricted diets are usually not required, but it is sensible to avoid very large amounts of strongly aged or fermented foods and to discuss any dietary concerns with your clinician.

Q: Can rasagiline be taken with levodopa or other Parkinson medicines?
A: Yes, it is commonly used together with levodopa and sometimes with other Parkinson drugs to smooth out symptom control, though levodopa doses may need adjustment to limit dyskinesias and other side effects.

Q: What happens if I stop rasagiline suddenly?
A: Stopping abruptly is not usually dangerous but may lead to a gradual worsening of Parkinson symptoms; any decision to stop or change dosing should be done with your prescribing clinician.

Q: Is rasagiline safe to use during pregnancy or breastfeeding?
A: There is limited human data on rasagiline in pregnancy and breastfeeding, so it is generally used only if the expected benefits clearly outweigh potential risks, after careful discussion between the patient and clinician.

Storage
Store rasagiline tablets at room temperature away from moisture, heat, and direct light, and keep the bottle tightly closed and out of reach of children and pets.

Disposal
Do not flush leftover tablets unless specifically instructed; use a community drug take-back program or follow pharmacist/local guidelines for safe disposal in household trash (for example, mixing tablets with an undesirable substance in a sealed container).